Madrigal Pharmaceuticals
500 Office Center Drive
Suite 400
Fort Washington
Pennsylvania
19034
United States
Tel: 267-327-4445
Website: http://www.madrigalpharma.com/
Email: info@madrigalpharma.com
96 articles about Madrigal Pharmaceuticals
-
Madrigal Pharmaceuticals to Participate in the JMP Securities Life Sciences Conference
5/11/2023
Madrigal Pharmaceuticals, Inc. announced today its management team will participate in a fireside chat at the The JMP Securities Life Sciences Conference on Tuesday, May 16, 2023 at 10:30 am ET.
-
Madrigal Pharmaceuticals Provides Corporate Updates and Reports First Quarter 2023 Financial Results
5/9/2023
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis, provides a summary of corporate updates and reports first quarter 2023 financial results.
-
Madrigal Receives Breakthrough Therapy Designation from FDA for Resmetirom and Completes Enrollment of the Phase 3 MAESTRO-NASH Biopsy Trial
4/18/2023
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that resmetirom has received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for the treatment of patients with NASH with liver fibrosis.
-
Madrigal Pharmaceuticals Provides Corporate Updates and Reports 2022 Fourth Quarter and Full Year Financial Results
2/23/2023
Madrigal Pharmaceuticals, Inc. today provides a summary of corporate updates and reports fourth quarter and full year 2022 financial results.
-
Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences - February 8, 2023
2/8/2023
Madrigal Pharmaceuticals, Inc. announced today its management team will participate in three upcoming investor conferences.
-
Madrigal Announces Additional Positive Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH with Liver Fibrosis
1/6/2023
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced additional results from the pivotal Phase 3 MAESTRO-NASH biopsy clinical trial of resmetirom, a liver-directed selective thyroid hormone receptor agonist.
-
Mergers and acquisitions are expected to be a key theme in the pharmaceutical industry in 2023.
-
2022's Top Clinical Advancements: See Pivotal Data in NASH, Alzheimer’s, Sickle Cell Disease
12/23/2022
2022 featured pivotal data that could change the landscape in non-alcoholic steatohepatitis, Alzheimer’s disease, sickle cell disease and many more indications. -
Madrigal Pharmaceuticals Announces $300+ Million in Financing Events to Advance Resmetirom Program
12/21/2022
Madrigal Pharmaceuticals, Inc. announced that it has raised $259 million in gross equity from equity securities issuances and an additional $50 million in liquidity commitments following the achievement of the clinical milestone under its Hercules Credit Facility.
-
Madrigal's NASH drug hits the mark in late-stage trial.
-
Madrigal Announces Positive Topline Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH and Liver Fibrosis
12/19/2022
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced positive topline results from the pivotal Phase 3 MAESTRO-NASH biopsy clinical trial of resmetirom, a liver-directed selective thyroid hormone receptor agonist.
-
Madrigal Pharmaceuticals To Announce Topline Results from the Phase 3 MAESTRO-NASH Study of Resmetirom on Monday, December 19th
12/18/2022
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis, plans to announce topline results from the Phase 3 MAESTRO-NASH study of resmetirom on Monday, December 19th, 2022.
-
Madrigal Pharmaceuticals Provides an Overview of Upcoming Resmetirom Data Presentations and Reports 2022 Third Quarter Financial Results
11/3/2022
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis, provides an overview of upcoming resmetirom Phase 3 data presentations and reports third quarter 2022 financial results.
-
Madrigal Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
9/7/2022
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), announced today its management team will participate in a fireside chat at the H.C. Wainwright 24th Annual Global Investment Conference on Monday, September 12, 2022 at 9:30 am ET.
-
Madrigal Pharmaceuticals Initiates the MAESTRO-NASH Outcomes Study Evaluating Resmetirom for the Treatment of Patients with Compensated NASH Cirrhosis
8/31/2022
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), today announced initiation of the “MAESTRO-NASH Outcomes” study of resmetirom (recruiting, first patient screened). MAESTRO-NASH Outcomes is a Phase 3, double-blind, randomized, placebo-controlled study that will noninvasively measure progression to liver decompensation events in approximately 700 patients with compensated NASH cirrhosis.
-
Madrigal Pharmaceuticals Provides Clinical and Business Updates and Reports 2022 Second Quarter Financial Results
8/4/2022
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today provides a summary of recent corporate accomplishments and reports its second quarter 2022 financial results.
-
Madrigal Pharmaceuticals Presents Late-Breaking Phase 3 NASH Data and Multiple Oral Abstracts at EASL’s International Liver Congress™
6/25/2022
Madrigal Pharmaceuticals, Inc. announced data from multiple resmetirom abstracts presented at the European Association for the Study of the Liver’s International Liver Congress, including a late-breaking presentation of data from the Phase 3 MAESTRO-NAFLD-1 study and three additional oral presentations from the resmetirom clinical development program.
-
Madrigal Pharmaceuticals Supports International NASH Day on June 9
6/6/2022
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatitis, announced its support for the fifth International NASH Day, taking place on June 9, 2022.
-
Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences
6/2/2022
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatitis, announced its management team will participate in three upcoming investor conferences.
-
Madrigal Pharmaceuticals Announces Participation at Two Upcoming Investor Conferences
5/17/2022
Madrigal Pharmaceuticals, Inc. announced its management team will participate in two upcoming investor conferences.